Clearmind Medicine Completes Dosing for All Participants in CMND-100 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Clearmind Medicine announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clearmind Completes Dosing for Phase I/II Trial of CMND-100
- Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed dosing for all 24 participants in its CMND-100 drug trial, marking the completion of Part A of its Phase I/II clinical trial, indicating the company's potential in treating Alcohol Use Disorder.
- Recruitment Efficiency: The trial is conducted at multiple clinical centers, including Yale School of Medicine and Johns Hopkins University, with all sites demonstrating rapid patient recruitment and efficient treatment timelines, showcasing the company's execution capabilities in clinical settings.
- Positive Safety Results: Interim results indicate a strong safety profile from the first three cohorts, providing confidence for the company as it advances this important program under FDA oversight, potentially paving the way for future drug approvals.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen drug market.
See More
Biotech Stocks Show Significant Pre-Market Movements
- Significant Pre-Market Gains: Bio Green Med Solution, Inc. (BGMS) surged 182% to $3.01 in pre-market trading, indicating strong market reaction to potential acquisition agreements, which may attract further investor interest.
- Other Gaining Stocks: Clearmind Medicine Inc. (CMND) rose 37% to $4.03, while BioCardia, Inc. (BCDA) increased by 30% to $1.19, suggesting that financing deals are boosting investor confidence in the biotech sector, potentially leading to a surge in subsequent investments.
- Pre-Market Decliners: Indaptus Therapeutics, Inc. (INDP) fell 36% to $3.04, reflecting market concerns over its financial health, which may prompt investors to reassess its future outlook.
- Other Declining Stocks: Zhongchao Inc. (ZCMD) dropped 16% to $0.03, and Aditxt, Inc. (ADTX) decreased by 14% to $0.06, indicating a weakening market confidence in these companies, which could impact their future financing capabilities.
See More
Clearmind Medicine to Host Webinar on MEAI Clinical Data
- Webinar Announcement: Clearmind Medicine Inc. will host a webinar on June 10, 2026, featuring researchers from Yale and Johns Hopkins, aimed at sharing the latest clinical data on CMND-100 for Alcohol Use Disorder, which is expected to attract broad public participation.
- Clinical Trial Progress: The ongoing FDA-approved Phase I/IIa multi-center trial evaluating the efficacy of the non-hallucinogenic drug CMND-100 shows potential therapeutic value for Alcohol Use Disorder, potentially addressing significant under-treated health issues.
- Expert Lineup: The webinar will feature Dr. Anahita Bassir Nia from Yale and Dr. Jennifer Ellis from Johns Hopkins, both of whom have extensive research experience in psychedelics and novel therapeutics, enhancing the professionalism and authority of the session.
- Company Strategic Goals: Clearmind is focused on developing non-hallucinogenic neuroplastogen-derived therapeutics, currently holding 19 patent families and 31 granted patents, with plans to expand its intellectual property portfolio to support long-term growth in the mental health sector.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Clearmind Secures Patent and Clinical Approval for Alcohol Use Disorder Treatment
- Patent Progress: Clearmind's patent application in Japan covers its proprietary MEAI formulation, which is being utilized to develop therapies for depression, weight loss, and alcohol use disorder, potentially enhancing its competitive edge in the biotech sector.
- Clinical Trial Approval: Earlier this week, Clearmind received approval from the Johns Hopkins Medicine Institutional Review Board to conduct a Phase I/II clinical trial for CMND-100, an MEAI-based oral candidate targeting alcohol use disorder, which has shown good safety and tolerability.
- Stock Surge: Following the patent announcement, Clearmind's shares soared approximately 40% on Friday, marking the largest single-day gain since the company executed a 1-for-10 reverse stock split, reflecting strong market interest in its new therapies.
- Investor Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'extremely bullish' within a day, with extremely high message volumes indicating optimism about Clearmind's future performance, potentially driving the stock price past $10.
See More
Clearmind Files Japanese Patent Application, Strengthening Antidepressant Development
- Patent Application Filed: Clearmind Medicine Inc. has announced the publication of a Japanese patent application for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, further strengthening its global intellectual property portfolio, which includes 31 granted patents.
- Significant Market Potential: The global market for anxiety and depression treatments is projected to reach $19-30 billion by 2030-2031, driven by rising mental health awareness and demand for innovative therapies, positioning Clearmind's MEAI molecule favorably in this rapidly growing sector.
- Demand in Japan: With approximately 3 million diagnosed cases of Major Depressive Disorder (MDD) in Japan, exacerbated by societal factors like work-related stress, Clearmind's MEAI offers a safer treatment alternative, addressing the increasing demand in this market.
- Pipeline Expansion: Clearmind is expanding its MEAI-based pipeline to include research into alcohol use disorder and metabolic conditions, thereby reinforcing its market position in the neuroplastogen and mental health therapeutics space.
See More
Clearmind Completes Dosing for Phase I/II Trial of CMND-100
- Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed dosing for all 24 participants in its CMND-100 drug trial, marking the completion of Part A of its Phase I/II clinical trial, indicating the company's potential in treating Alcohol Use Disorder.
- Recruitment Efficiency: The trial is conducted at multiple clinical centers, including Yale School of Medicine and Johns Hopkins University, with all sites demonstrating rapid patient recruitment and efficient treatment timelines, showcasing the company's execution capabilities in clinical settings.
- Positive Safety Results: Interim results indicate a strong safety profile from the first three cohorts, providing confidence for the company as it advances this important program under FDA oversight, potentially paving the way for future drug approvals.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen drug market.
See More
Biotech Stocks Show Significant Pre-Market Movements
- Significant Pre-Market Gains: Bio Green Med Solution, Inc. (BGMS) surged 182% to $3.01 in pre-market trading, indicating strong market reaction to potential acquisition agreements, which may attract further investor interest.
- Other Gaining Stocks: Clearmind Medicine Inc. (CMND) rose 37% to $4.03, while BioCardia, Inc. (BCDA) increased by 30% to $1.19, suggesting that financing deals are boosting investor confidence in the biotech sector, potentially leading to a surge in subsequent investments.
- Pre-Market Decliners: Indaptus Therapeutics, Inc. (INDP) fell 36% to $3.04, reflecting market concerns over its financial health, which may prompt investors to reassess its future outlook.
- Other Declining Stocks: Zhongchao Inc. (ZCMD) dropped 16% to $0.03, and Aditxt, Inc. (ADTX) decreased by 14% to $0.06, indicating a weakening market confidence in these companies, which could impact their future financing capabilities.
See More
Clearmind Medicine to Host Webinar on MEAI Clinical Data
- Webinar Announcement: Clearmind Medicine Inc. will host a webinar on June 10, 2026, featuring researchers from Yale and Johns Hopkins, aimed at sharing the latest clinical data on CMND-100 for Alcohol Use Disorder, which is expected to attract broad public participation.
- Clinical Trial Progress: The ongoing FDA-approved Phase I/IIa multi-center trial evaluating the efficacy of the non-hallucinogenic drug CMND-100 shows potential therapeutic value for Alcohol Use Disorder, potentially addressing significant under-treated health issues.
- Expert Lineup: The webinar will feature Dr. Anahita Bassir Nia from Yale and Dr. Jennifer Ellis from Johns Hopkins, both of whom have extensive research experience in psychedelics and novel therapeutics, enhancing the professionalism and authority of the session.
- Company Strategic Goals: Clearmind is focused on developing non-hallucinogenic neuroplastogen-derived therapeutics, currently holding 19 patent families and 31 granted patents, with plans to expand its intellectual property portfolio to support long-term growth in the mental health sector.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Clearmind Secures Patent and Clinical Approval for Alcohol Use Disorder Treatment
- Patent Progress: Clearmind's patent application in Japan covers its proprietary MEAI formulation, which is being utilized to develop therapies for depression, weight loss, and alcohol use disorder, potentially enhancing its competitive edge in the biotech sector.
- Clinical Trial Approval: Earlier this week, Clearmind received approval from the Johns Hopkins Medicine Institutional Review Board to conduct a Phase I/II clinical trial for CMND-100, an MEAI-based oral candidate targeting alcohol use disorder, which has shown good safety and tolerability.
- Stock Surge: Following the patent announcement, Clearmind's shares soared approximately 40% on Friday, marking the largest single-day gain since the company executed a 1-for-10 reverse stock split, reflecting strong market interest in its new therapies.
- Investor Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'extremely bullish' within a day, with extremely high message volumes indicating optimism about Clearmind's future performance, potentially driving the stock price past $10.
See More
Clearmind Files Japanese Patent Application, Strengthening Antidepressant Development
- Patent Application Filed: Clearmind Medicine Inc. has announced the publication of a Japanese patent application for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, further strengthening its global intellectual property portfolio, which includes 31 granted patents.
- Significant Market Potential: The global market for anxiety and depression treatments is projected to reach $19-30 billion by 2030-2031, driven by rising mental health awareness and demand for innovative therapies, positioning Clearmind's MEAI molecule favorably in this rapidly growing sector.
- Demand in Japan: With approximately 3 million diagnosed cases of Major Depressive Disorder (MDD) in Japan, exacerbated by societal factors like work-related stress, Clearmind's MEAI offers a safer treatment alternative, addressing the increasing demand in this market.
- Pipeline Expansion: Clearmind is expanding its MEAI-based pipeline to include research into alcohol use disorder and metabolic conditions, thereby reinforcing its market position in the neuroplastogen and mental health therapeutics space.
See More
